What are the risks and safety concerns associated with NAD (nicotinamide adenine dinucleotide) infusions?

NAD Infusions Carry Significant Tolerability Concerns and Lack Established Safety Standards

NAD infusions are not inherently "dangerous" in terms of mortality risk, but they frequently cause moderate to severe side effects during administration and lack rigorous safety evaluation through standard regulatory pathways. The available evidence suggests these infusions should be approached with caution, particularly given the absence of FDA approval for anti-aging or wellness indications.

Safety Profile Based on Available Evidence

Acute Tolerability Issues

The most comprehensive direct comparison of NAD administration routes found that intravenous NAD+ infusions caused moderate to severe symptoms including gastrointestinal distress, increased heart rate, and chest pressure during infusions 1. These symptoms were significant enough to require dramatically slower infusion rates—averaging 97 minutes versus 37 minutes for the better-tolerated nicotinamide riboside (NR) alternative 1.

In contrast, studies using NAD infusions for substance use disorder reported the procedure was completed in approximately 1,000 infusions across 900 patients "without any serious side effects" 2, though this retrospective review did not systematically capture or grade adverse events using standardized criteria.

Biochemical Safety Markers

Short-term biochemical safety appears acceptable based on limited data. Studies evaluating liver enzymes (ALT, AST) showed no significant elevations 1. One study noted a decrease in alkaline phosphatase that remained within normal ranges 1. However, these assessments were limited to 30-day follow-up periods at most.

Critical Evidence Gaps

The most concerning aspect is what we don't know:

• No randomized controlled trials have evaluated intravenous NAD+ for anti-aging or wellness indications 3
• The one identified intravenous NMN study was nonrandomized and primarily provided short-term safety data only 3
• Long-term safety beyond several weeks remains completely uncharacterized 3
• Doses used in commercial wellness settings (often 500-1000 mg) lack standardized protocols or regulatory oversight

Comparison to Established NAD Precursor Safety

For context, oral NAD+ precursors have much better safety documentation:

• Nicotinamide (vitamin B3) has an established upper limit of 900 mg/day for adults based on extensive safety data 4
• Nicotinic acid has a lower upper limit of 10 mg/day due to flushing and potential hypotensive episodes, particularly in elderly patients 4
• Oral NR and NMN supplementation (250-2000 mg/day) showed favorable tolerability in systematic reviews, with no clear increase in adverse events over weeks to months 5, 3

Clinical Context and Recommendations

When NAD Infusions May Be Considered

The only clinical context with published evidence supporting NAD infusions is substance use disorder treatment, where studies showed significant reductions in craving scores, anxiety, and depression 2, 6. Even here, the evidence consists of retrospective case series rather than controlled trials.

Red Flags and Contraindications

Based on the known pharmacology of NAD precursors, exercise particular caution with:

• Patients with cardiovascular instability (given reports of chest pressure and tachycardia during infusion) 1
• Elderly patients (increased risk of hypotensive episodes with high-dose niacin compounds) 4
• Patients with liver disease (though short-term data is reassuring, high-dose niacin can cause hepatotoxicity at gram doses) 4
• Patients with asthma (if adenosine is co-administered, as it can cause severe bronchospasm) 7

Practical Safety Measures If Proceeding

If NAD infusions are administered despite limited evidence:

1. Start with slower infusion rates (the 97-minute average from comparative data suggests this is necessary for tolerability) 1
2. Monitor vital signs continuously during infusion, particularly heart rate and blood pressure
3. Have the patient remain under observation for at least 30-60 minutes post-infusion
4. Obtain baseline and follow-up liver enzymes if planning repeated infusions
5. Document all adverse events systematically to contribute to the safety knowledge base

The Fundamental Problem

The commercial availability of NAD infusions has far outpaced the scientific evidence supporting their use. While oral NAD+ precursors have demonstrated biochemical target engagement and acceptable safety profiles in controlled studies 8, 5, 3, the leap to intravenous administration bypasses normal physiologic regulation and lacks the rigorous evaluation expected for medical interventions.

The FDA drug label evidence provided 9 pertains to topical cosmetic products containing NAD, not intravenous formulations, highlighting the regulatory gap for parenteral NAD products marketed in wellness settings.

Bottom Line

NAD infusions are not acutely life-threatening based on available reports, but they cause frequent uncomfortable side effects during administration and lack the long-term safety data that would be required for FDA approval. The risk-benefit calculation currently favors oral NAD+ precursors (NR or NMN) over intravenous NAD+ for anti-aging or wellness purposes, as these have comparable biochemical effects with better tolerability and more established safety profiles 1, 3.

For patients seeking NAD augmentation, oral supplementation with established precursors represents a safer, evidence-based alternative unless there is a specific clinical indication (such as severe substance use disorder) where the potential benefits might justify the tolerability concerns and evidence gaps of intravenous administration.